Orexigen Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 7, 2013 /PRNewswire/ — Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are as follows:
The 15th Annual BIO CEO & Investor Conference Date: Tuesday, February 12, 2013 Time: 2:00 p.m. Eastern Time Location: The Waldorf Astoria, New York 2013 Leerink Swann Global Healthcare Conference Date: Wednesday, February 13, 2013 Time: 11:30 a.m. Eastern Time Location: The Waldorf Astoria, New York
The BIO CEO & Investor Conference presentation will be webcast live. To access the webcast, please visit the Investor Relations section of the company’s Web site at www.orexigen.com. A replay will be available for 14 days after the event.
About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company’s lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company’s other product candidate, Empatic(TM), has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.
VP, Corporate Communications and Business Development
SOURCE Orexigen Therapeutics, Inc.